MX2022007336A - Composiciones farmaceuticas intranasales de inhibidores de cgrp. - Google Patents
Composiciones farmaceuticas intranasales de inhibidores de cgrp.Info
- Publication number
- MX2022007336A MX2022007336A MX2022007336A MX2022007336A MX2022007336A MX 2022007336 A MX2022007336 A MX 2022007336A MX 2022007336 A MX2022007336 A MX 2022007336A MX 2022007336 A MX2022007336 A MX 2022007336A MX 2022007336 A MX2022007336 A MX 2022007336A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- cgrp
- intranasal pharmaceutical
- cgrp inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 3
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/007—Syringe-type or piston-type sprayers or atomisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949351P | 2019-12-17 | 2019-12-17 | |
| PCT/US2020/065452 WO2021127070A1 (en) | 2019-12-17 | 2020-12-17 | Intranasal pharmaceutical compositions of cgrp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007336A true MX2022007336A (es) | 2022-09-19 |
Family
ID=76478147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007336A MX2022007336A (es) | 2019-12-17 | 2020-12-17 | Composiciones farmaceuticas intranasales de inhibidores de cgrp. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220401439A1 (https=) |
| EP (1) | EP4076395A4 (https=) |
| JP (1) | JP2023507094A (https=) |
| KR (1) | KR20220114613A (https=) |
| CN (1) | CN114980862A (https=) |
| AU (1) | AU2020408705A1 (https=) |
| BR (1) | BR112022011892A2 (https=) |
| CA (1) | CA3164445A1 (https=) |
| IL (1) | IL293647A (https=) |
| MX (1) | MX2022007336A (https=) |
| WO (1) | WO2021127070A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12521389B2 (en) * | 2019-06-14 | 2026-01-13 | The Regents Of The University Of California | Therapeutic approach to lung disease |
| WO2022109077A1 (en) * | 2020-11-19 | 2022-05-27 | Biohaven Pharmaceutical Holding Company Ltd. | Compositions for improved delivery of cgrp inhibitors |
| JP1706573S (ja) * | 2021-02-15 | 2022-02-01 | 鼻スプレー器 | |
| WO2023064195A1 (en) * | 2021-10-11 | 2023-04-20 | Pfizer Ireland Pharmaceuticals | Cgrp antagonists for treating trigeminal neuralgia |
| CN115429882B (zh) * | 2022-10-19 | 2024-08-06 | 上海交通大学医学院附属第九人民医院 | 伤害性感觉神经细胞调控药物的用途 |
| CA3252054A1 (en) | 2022-11-09 | 2024-05-16 | Tapi Czech Industries S.R.O. | SOLID FORMS OF ZAVÉGÉPANT HYDROCHLORIDE AND THEIR PREPARATION PROCESS |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
| JP1773931S (ja) * | 2023-05-17 | 2024-06-25 | 鼻スプレー器 | |
| CA225743S (fr) * | 2023-05-17 | 2024-09-12 | Aptar France Sas | Dispositif pour spray nasal |
| CA225744S (fr) * | 2023-05-17 | 2024-09-12 | Aptar France Sas | Dispositif pour spray nasal |
| GB202308123D0 (en) * | 2023-05-31 | 2023-07-12 | Orexo Ab | New copmosition |
| CN120733002B (zh) * | 2025-09-03 | 2025-11-25 | 华中科技大学同济医学院附属同济医院 | Cgrp受体小分子拮抗剂在制备治疗嗜酸性慢性鼻窦炎伴鼻息肉的药品中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040076587A1 (en) * | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
| US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US20160199600A1 (en) * | 2013-09-11 | 2016-07-14 | Bixa Research And Health Inc. | Single use intranasal atomizer |
| WO2017001433A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| KR102444717B1 (ko) * | 2016-04-15 | 2022-09-16 | 하. 룬드벡 아크티에셀스카브 | 인간화 항-pacap 항체 및 그의 용도 |
| CN109476639B (zh) * | 2016-07-22 | 2021-02-26 | 橘生药品工业股份有限公司 | 吡咯烷衍生物 |
| US20190135927A1 (en) * | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| MX2020009856A (es) * | 2018-03-25 | 2020-10-08 | Biohaven Pharm Holding Co Ltd | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). |
| AU2020259461A1 (en) * | 2019-04-18 | 2021-11-11 | Allergan Sales, Llc | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
-
2020
- 2020-12-17 CN CN202080086534.4A patent/CN114980862A/zh active Pending
- 2020-12-17 MX MX2022007336A patent/MX2022007336A/es unknown
- 2020-12-17 US US17/769,966 patent/US20220401439A1/en not_active Abandoned
- 2020-12-17 AU AU2020408705A patent/AU2020408705A1/en active Pending
- 2020-12-17 WO PCT/US2020/065452 patent/WO2021127070A1/en not_active Ceased
- 2020-12-17 KR KR1020227024199A patent/KR20220114613A/ko active Pending
- 2020-12-17 JP JP2022535816A patent/JP2023507094A/ja active Pending
- 2020-12-17 BR BR112022011892A patent/BR112022011892A2/pt not_active Application Discontinuation
- 2020-12-17 EP EP20903976.7A patent/EP4076395A4/en not_active Withdrawn
- 2020-12-17 CA CA3164445A patent/CA3164445A1/en active Pending
- 2020-12-17 IL IL293647A patent/IL293647A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021127070A1 (en) | 2021-06-24 |
| US20220401439A1 (en) | 2022-12-22 |
| KR20220114613A (ko) | 2022-08-17 |
| EP4076395A1 (en) | 2022-10-26 |
| CA3164445A1 (en) | 2021-06-24 |
| CN114980862A (zh) | 2022-08-30 |
| EP4076395A4 (en) | 2024-02-07 |
| JP2023507094A (ja) | 2023-02-21 |
| BR112022011892A2 (pt) | 2022-09-06 |
| IL293647A (en) | 2022-08-01 |
| AU2020408705A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007336A (es) | Composiciones farmaceuticas intranasales de inhibidores de cgrp. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| PH12022552056A1 (en) | Heterocyclic glp-1 agonists | |
| PH12022551454A1 (en) | Pyrazolyl derivatives useful as anti-cancer agents | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| SA521421645B1 (ar) | بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30 | |
| MX2017010858A (es) | Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6. | |
| PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| MX2020005944A (es) | Analogos espirobiciclicos novedosos. | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| MX2022006736A (es) | Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas. | |
| PH12021550687A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| EP4306541A3 (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| PH12019500731A1 (en) | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors | |
| ZA202002762B (en) | Benzimidazole derivatives and their uses | |
| MX2021013318A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| GEP20257794B (en) | Magl inhibitor | |
| MX2025012658A (es) | Composicion farmaceutica que contiene oseltamivir | |
| EP4670791A3 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MX2024007457A (es) | Formas cristalinas de n-(6-amino-5-metilpiridin-3-il)-2-(benzo[d]t iazol-5-il)-5- metilpiperidin-1-il)-2-oxoacetamida, composiciones farmacéuticas y métodos de uso de estas. | |
| MX2023006164A (es) | Inhibidor de la progresion de la fibrosis. | |
| MX2024015057A (es) | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa-1 y composiciones farmaceuticas que los comprenden |